Foundation date



#Biotechnology - Therapeutics


eTheRNA BVBA is a spin-off company from VUB. The company was created in 2013 by Prof. Kris Thielemans out of the Laboratory of Molecular and Cellular Therapy (LMCT). eTheRNA is currently focused on the manufacturing of mRNA based drugs/vaccines to support clinical development and diagnostic applications. The aim is to grow into a Flanders based biopharma company that will develop a leadership position in not only mRNA manufacturing but also developing mRNA based drugs that enhance the immunological response against certain targeted diseases/indications.

News by etherna

  • mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers investing in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA

    Tuesday August 23rd 2022

  • eTheRNA Manufacturing announces new LNP formulation development and production service

    Tuesday March 29th 2022

  • eTheRNA announces research agreement with Merck to access mRNA technologies

    Thursday February 3rd 2022

Jobs by etherna